Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration (ReSCInD)

Trial status: Authorised All secondary endpoints are analyzed descriptively, and differences between the two study arms are explored according to their level of measurement. The primary endpoint, IL-1 β concentration in the blood within 24±6 hrs after symptom onset, will be analyzed in the full analysis set, which comes as close as possible to the IIT principle. A mixed linear regression model is calculated with the IL-1 β value (at 24±6hrs & 3 d) as the dependent variable, the randomized group, the IL-1 β value at baseline & the time point, the interaction of time + group, as independent variables and the patient as a random effect.

All secondary endpoints are analyzed descriptively, and differences between the two study arms are explored according to their level of measurement.

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 36 participants